- Home
- XENE vs TBBK Comparison
XENE vs TBBK Comparison
Compare XENE & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XENE | TBBK |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2014 | 2004 |
Fundamental Metrics
Financial Performance| Metric | XENE | TBBK |
|---|---|---|
| Price | $40.38 | $58.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $54.09 | ★ $69.33 |
| AVG Volume (30 Days) | ★ 954.8K | 680.9K |
| Earning Date | 02-26-2026 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.69 |
| EPS | N/A | ★ 4.92 |
| Revenue | $7,500,000.00 | ★ $526,150,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.37 |
| P/E Ratio | ★ N/A | $12.24 |
| Revenue Growth | N/A | ★ 6.21 |
| 52 Week Low | $26.74 | $40.51 |
| 52 Week High | $46.60 | $81.65 |
Technical Indicators
Market Signals| Indicator | XENE | TBBK |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 35.00 |
| Support Level | $40.43 | $58.50 |
| Resistance Level | $43.70 | $63.88 |
| Average True Range (ATR) | 1.58 | 3.60 |
| MACD | -0.04 | -1.19 |
| Stochastic Oscillator | 23.81 | 1.95 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.